| Nov 13 |
Q2 2024 Roivant Sciences Ltd Earnings Call
|
| Nov 8 |
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
|
| Nov 7 |
Immunovant GAAP EPS of -$0.74
|
| Nov 7 |
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
|
| Oct 29 |
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
|
| Oct 14 |
Immunovant: Switching Lead Candidates Increases Risk
|
| Oct 1 |
Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?
|
| Sep 30 |
Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy?
|
| Sep 9 |
Immunovant stock falls 8% amid Graves' disease program update
|
| Sep 9 |
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
|
